AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11272721
Drug: HEP A
RxNorm normalized name: Hep A, IG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEP A & B vaccines concurrently (HEP A: 25 units in 0.5 mL; HEP B: 10 micrograms in 1.0 mL)
Trial: 11272721
Drug: HEP B
RxNorm normalized name: Bayhep B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEP B vaccine (10 micrograms in 1.0 mL)
Trial: 9517592
Drug: Inhaled NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled NO concentration of 20 ppb
Trial: 9517592
Drug: Inhaled NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled NO concentrations of 49 ppb, 98 ppb, and 148 ppb
Trial: 2488113
Drug: Propranolol (PPL)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (PPL) 180-240 mg
Trial: 2488113
Drug: Pindolol (PDL)
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol (PDL) 15-45 mg
Trial: 769949
Drug: Standard-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cyclophosphamide (3 mg/kg/day)
Trial: 769949
Drug: Intermittent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent high-dose cyclophosphamide (10 mg/kg/day for 4 days out of 14)
Trial: 769949
Drug: Cyclophosphamide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (3 mg/kg/day) plus cytosine arabinoside (3 mg/kg/week im)
Trial: 31764989
Drug: Sodium thiosulphate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium thiosulphate (NaTS) 25 g/1.73 m2
Trial: 27827284
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (ESWT)
Trial: 21802630
Drug: Clonidine group
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine group (n = 40) received 4.5 mL of lidocaine‐bupivacaine and 0.5 μg/kg of clonidine in a 0.5 mL volume
Trial: 16647884
Drug: Tiagabine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine monotherapy
Trial: 12297808
Drug: Gatifloxacin 400
RxNorm normalized name: gatifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 400 mg once daily for 10 days
Trial: 8542742
Drug: Insulin-dependent diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetic patients without complications
Trial: 8542742
Drug: Insulin-dependent diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-dependent diabetic patients with microvascular disease
Trial: 21512411
Drug: EBTA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBTA group (Esomeprazole, Bismuth subcitrate, Tetracycline, Amoxicillin)
Trial: 17130343
Drug: Probenecid 1000
RxNorm normalized name: probenecid 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid 1000 mg
Trial: 31719005
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C
Trial: 15311720
Drug: EZE +
RxNorm normalized name: Acetaminophen 650 MG Oral Tablet [PAIN-EZE +/RHEU-THRITIS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE + ATV 10 mg
Trial: 9067720
Drug: Sillix Donna
RxNorm normalized name: ATROPA BELLA-DONNA FLOWERING TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sillix Donna (active preparation)
Trial: 2946313
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of fentanyl and alfentanil
Trial: 31655134
Drug: Glecaprevir-pibrentasvir 300
RxNorm normalized name: glecaprevir / pibrentasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks with simplified monitoring
Trial: 31655134
Drug: Standard monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard monitoring with glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks
Trial: 31556670
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy (MET) combined with cognitive-behavioral therapy (CBT)
Trial: 24831251
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) alone
Trial: 31556670
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU; 12-step facilitation, supportive therapy)
Trial: 28586233
Drug: DentalVibe® Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DentalVibe® Injection Comfort System (DV3)
Trial: 23458449
Drug: Complete steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete steroids avoidance (n = 50)
Trial: 23458449
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 50)
Trial: 14628279
Drug: Hydroxyurea (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (500 mg bid) plus didanosine (400 mg qd)
Trial: 1868748
Drug: Naftifine gel
RxNorm normalized name: naftifine Topical Gel
DrugBank: Naftifine (DB00735)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naftifine gel 1 percent
Trial: 3048914
Drug: Naftifine cream
RxNorm normalized name: naftifine Topical Cream
DrugBank: Naftifine (DB00735)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naftifine cream 1 percent
Trial: 2805810
Drug: Econazole nitrate
RxNorm normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Econazole nitrate cream 1 percent
Trial: 2805810
Drug: Clotrimazole cream
RxNorm normalized name: Clotrimazole Cream
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole cream 1 percent
Trial: 31515250
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (PEG) therapy
Trial: 22976131
Drug: 21/2 placebo/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21/2 placebo/5 ethinyl estradiol 10 μg regimen (group 2)
Trial: 17346247
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill
Trial: 10653925
Drug: Aggressive cholesterol-lowering
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive cholesterol-lowering therapy with atorvastatin
Trial: 1658953
Drug: Nonoxynol-9 (N-9),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoxynol-9 (N-9), 150 mg, used cumulatively four times a day for 14 days
Trial: 31600598
Drug: XF-73 2.0mg/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XF-73 2.0mg/g 2% gel
Trial: 31226190
Drug: Conventional implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implant planning and freehand placement (control group, n = 26)
Trial: 31226190
Drug: Conventional implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implant planning and freehand placement (control group)
Trial: 25032713
Drug: Regular-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-dose atorvastatin (10 mg)
Trial: 22972399
Drug: High-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose atorvastatin (80 mg)
Trial: 24858750
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg lycopene/day for 2 weeks with oral prophylaxis (full mouth scaling and root planing completed within 24 hours)
Trial: 29217959
Drug: Oral prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis only
Trial: 21996647
Drug: Parecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (40 mg intravenous infusion)
Trial: 1647496
Drug: Sumatriptan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (6 mg subcutaneous injection)
Trial: 19243818
Drug: IL-12 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-12 300 ng/kg subcutaneously twice weekly for 24 weeks
Trial: 19243818
Drug: IL-12 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks (initial treatment)
Trial: 16521225
Drug: CIFN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIFN with polaprezinc 300 mg (regimen A, n=41)
Trial: 3295620
Drug: Monthly myelosuppressive
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly myelosuppressive maintenance chemotherapy after TAD9-induction and consolidation
Trial: 27406394
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg twice daily) plus metformin [500 mg twice daily] (VLDM group)
Trial: 27406394
Drug: Metformin uptitration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin uptitration [1000 mg twice daily] (HDM group)
Trial: 7837862
Drug: Standard ORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ORS (311 mmol/L)
Trial: 31215874
Drug: 18% ethylenediaminetetraacetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18% ethylenediaminetetraacetic acid (EDTA) water solution
Trial: 30019676
Drug: 150 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 μg iodine/day from a multivitamin supplement for pregnant and lactating women
Trial: 23047502
Drug: Sodium ferulate
RxNorm normalized name: ferulate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferulate (SF) 150 mg three times daily for fourteen days
Trial: 19941078
Drug: Intranasal mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal mometasone
Trial: 2964995
Drug: Nebulized ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized ipratropium bromide and salbutamol therapy (combined)
Trial: 2964995
Drug: Nebulized ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized ipratropium bromide and salbutamol therapy (separately)
Trial: 31017585
Drug: Weekly serial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly serial self-measurements of waist and hip circumference combined with motivational text messages for 8 weeks
Trial: 23642330
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Anorexia Nervosa (CBT-AN)
Trial: 20073139
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention to improve medication adherence
Trial: 17196664
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (bifrontal and right unilateral ECT)
Trial: 3061715
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution (dilute and hyperosmolar)
Trial: 3061715
Drug: Hyperosmolar saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperosmolar saline solution
Trial: 31953540
Drug: Very Low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very Low Carbohydrate (VLC) diet (14%E carbohydrate, <50 g/d; 28%E protein; 58%E fat)
Trial: 25925398
Drug: Peanut oral
RxNorm normalized name: Peanut Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oral escalating immunotherapy
Trial: 11762557
Drug: Ortho Evra
RxNorm normalized name: Ortho Evra
DrugBank: Norelgestromin (DB06713)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ortho Evra contraceptive patch
Trial: 8669219
Drug: Cimetidine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1200 mg) administered by infusion pump over 24 hrs
Trial: 8669219
Drug: Ranitidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (200 mg) administered by infusion pump over 24 hrs
Trial: 2677055
Drug: Oral flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral flurbiprofen (100 mg/day) + toothbrushing (A)
Trial: 2677055
Drug: Oral flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral flurbiprofen (100 mg/day) only (C)
Trial: 699626
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg diflunisal twice daily
Trial: 6544198
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen 3-times daily
Trial: 24998009
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections
Trial: 25467848
Drug: PBT2 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBT2 100 mg
Trial: 22808020
Drug: Oral rinse
RxNorm normalized name: Oral Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rinse (60 seconds with chlorhexidine followed by 60 seconds with nystatin)
Trial: 22808020
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral rinse
Trial: 19165563
Drug: Levosimendan (L)
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (L)
Trial: 15590210
Drug: HRT every
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT every day (0.625 mg CEE and 2.5 mg MPA)
Trial: 12199798
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) for 5-7 days
Trial: 12199798
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) reviparin for 5-7 days (short-treated group)
Trial: 12199798
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) reviparin for 28 days (long-treated group)
Trial: 1811606
Drug: Intravenous gamma
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gamma immunoglobulin (IVIG)
Trial: 30757935
Drug: Eclipta prostrata
RxNorm normalized name: ECLIPTA PROSTRATA LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eclipta prostrata (EP) 1 mg/day
Trial: 30757935
Drug: Eclipta prostrata
RxNorm normalized name: ECLIPTA PROSTRATA LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eclipta prostrata (EP) 10 mg/day
Trial: 30757935
Drug: Topical 3%
RxNorm normalized name: sulfur topical 3% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 3% minoxidil
Trial: 30289329
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine A (CsA) treatment (4 times daily in both eyes for a month before HSCT and continued use after transplantation)
Trial: 25923229
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (sequential therapy and modified bismuth-included quadruple therapy)
Trial: 17310303
Drug: Parecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (40 mg, administered twice within 12 h)
Trial: 17310303
Drug: Propacetamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol (2 g, administered twice within 12 h)
Trial: 15362796
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (group III)
Trial: 15362796
Drug: H2-receptor antagonist
RxNorm normalized name: H2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-receptor antagonist (group II)
Trial: 1530028
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group I)
Trial: 16060412
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 20 mg
Trial: 2697728
Drug: Benazepril 20
RxNorm normalized name: benazepril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 20 mg o.d.
Trial: 2697728
Drug: Benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 10 mg b.i.d.
Trial: 1505563
Drug: Benazepril 20
RxNorm normalized name: benazepril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 20 mg b.i.d.
Trial: 29953782
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery and six to eight courses of intravenous chemotherapy
Trial: 26346592
Drug: Vortioxetine 5
RxNorm normalized name: vortioxetine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 5 mg (elderly patients)
Trial: 30157357
Drug: L-carnitine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine combined with coenzyme Q10
Trial: 26864193
Drug: IP ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP ketorolac 30 mg + intravenous saline
Trial: 7549168
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac 30 mg
Trial: 26864193
Drug: Intraperitoneal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal saline + intravenous saline
Trial: 24827696
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection analgesia (PAI) - mixture of ropivacaine, saline, epinephrine, morphine hydrochloride, and dexamethasone
Trial: 16135141
Drug: UVB311 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVB311 nm therapy
Trial: 16135141
Drug: Broad-band UVB
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-band UVB therapy
Trial: 7828294
Drug: Nadolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (40 mg/d)
Trial: 7828294
Drug: Atenolol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (25 mg/d)
Trial: 7828294
Drug: Nadolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (20 mg/d)
Trial: 2200382
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg/d)
Trial: 30106956
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of mass azithromycin distribution
Trial: 30106956
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of continuation vs discontinuation
Trial: 21637969
Drug: Azelnidipine (8-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine (8-16 mg/day)
Trial: 21637969
Drug: Amlodipine (2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5-5 mg/day)
Trial: 19675101
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (62% ALA, 5.4 g/d)
Trial: 15382590
Drug: Manipulative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulative therapy (French method of R. Meigne)
Trial: 8100628
Drug: Syrup of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup of ipecac 30 ml followed by activated charcoal 50 g in sorbitol
Trial: 30892108
Drug: Cholestyramine 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine 15% Ointment applied twice a day for 2 months
Trial: 30892108
Drug: Placebo Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Ointment applied twice a day for 2 months
Trial: 22700888
Drug: Carvedilol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (50 mg twice daily)
Trial: 17013444
Drug: Peg‐IFNalpha‐2b 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFNalpha‐2b 1.5 mcg/kg QW x 48 weeks plus 800‐1200 mg ribavirin (Arm B)
Trial: 9272343
Drug: Various pertussis
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various pertussis vaccines
Trial: 29253089
Drug: Standard-Dose Influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Dose Influenza Vaccine (Fluviral, GSK)
Trial: 29253089
Drug: High-Dose Influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Influenza Vaccine (FluzoneHD, Sanofi)
Trial: 18770962
Drug: Suspension of
RxNorm normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of the vaginal apex to the uterosacral ligaments or sacrospinous ligaments
Trial: 15880023
Drug: Everolimus 0.75-1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 0.75-1.5 mg bid plus reduced-exposure cyclosporine (CsA) and prednisone
Trial: 10469713
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day danazol for 6 months
Trial: 1654756
Drug: 16-gauge intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-gauge intravenous catheter